secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nordicus Partners Corp (NORD)
CIK:        0001011060
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-044996
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares
----------------------------------------------------------------------------

- Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.
- Consideration: 12 million restricted common shares (OTCQB: NORD) issued to sellers.
- Bio-Convert is developing a drug for oral leukoplakia, a potentially malignant disorder.
- Nordicus previously acquired 95% of Orocidin A/S in May 2024, adding periodontitis therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224044996/0001493152-24-044996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224044996/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer